Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de 52 semanas para aprender sobre a segurança e os efeitos do ritlecitinibe em participantes com vitiligo não segmentar (Tranquillo LTE)

24 de setembro de 2026 atualizado por: Pfizer

UM ESTUDO DE EXTENSÃO MULTICENTRAL DE RETIRADA RANDOMIZADA DE FASE 3 E TITULAÇÃO DE DOSE, INVESTIGANDO A SEGURANÇA, EFICÁCIA E TOLERABILIDADE DE RITLECITINIB EM PARTICIPANTES ADULTOS E ADOLESCENTES COM VITILIGO NÃO SEGMENTAL

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).

Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin.

Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show:

  • if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo)
  • Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study
  • Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study.

This study is seeking for participants who:

  • have non-segmental vitiligo (either active or stable) and
  • received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it.

All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home.

Participants may receive the study medicine or placebo for up to 52 weeks.

The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo.

Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study.

Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Tipo de estudo

Intervencional

Inscrição (Real)

394

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Baden-Wurttemberg
      • Stuttgart, Baden-Wurttemberg, Alemanha, 70178
        • Praxis Leitz und Kollegen
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, Alemanha, 48455
        • Fachklinik Bad Bentheim
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Alemanha, 48149
        • Universitätsklinikum Münster
    • New South Wales
      • Darlinghurst, New South Wales, Austrália, 2010
        • The Skin Hospital
    • South Australia
      • Campbelltown, South Australia, Austrália, 5074
        • North Eastern Health Specialists
    • Victoria
      • Carlton, Victoria, Austrália, 3053
        • Skin Health Institute Inc.
      • East Melbourne, Victoria, Austrália, 3002
        • Dr Rodney Sinclair Pty Ltd
      • Melbourne, Victoria, Austrália, 3004
        • The Alfred Hospital
      • Stara Zagora, Bulgária, 6003
        • UMHAT "Prof. Dr. Stoyan Kirkovich"AD
    • Kyustendil
      • Dupnitsa, Kyustendil, Bulgária, 2600
        • Medical Centre "Asklepiy"
    • Sofia (stolitsa)
      • Sofia, Sofia (stolitsa), Bulgária, 1431
        • Diagnostic Consultative Center Aleksandrovska
      • Québec, Canadá, G1V 4X7
        • Centre de Recherche Dermatologique du Quebec metropolitain
      • Québec, Canadá, G1W 4R4
        • Centre de Recherche Saint-Louis inc.
    • Alberta
      • Calgary, Alberta, Canadá, T2J 7E1
        • Dermatology Research Institute
      • Red Deer, Alberta, Canadá, T4P 1K4
        • CaRe Clinic
    • Ontario
      • Markham, Ontario, Canadá, L3P 1X3
        • Lynderm Research Inc.
      • Mississauga, Ontario, Canadá, L4Y 4C5
        • DermEdge Research
      • Toronto, Ontario, Canadá, M2N3A6
        • North York Research Inc
    • Guangdong
      • Guangzhou, Guangdong, China, 510091
        • Dermatology Hospital of Southern Medical University
    • Hubei
      • Wuhan, Hubei, China, 430022
        • The First Hospital of Wuhan
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • The First Hospital of China Medical University/Dermatology and STD Department
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Huashan Hospital Fudan University
    • Yunnan
      • Kunming, Yunnan, China, 650032
        • First Affiliated Hospital of Kunming Medical University
    • Kyǒnggi-do
      • Suwon, Kyǒnggi-do, Coréia do Sul, 16247
        • The Catholic University Of Korea St. Vincent's Hospital
      • Suwon, Kyǒnggi-do, Coréia do Sul, 16499
        • Ajou University Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul, Seoul-teukbyeolsi [seoul], Coréia do Sul, 03722
        • Severance Hospital, Yonsei University Health System
      • Córdoba, Espanha, 14001
        • AUDIKA
    • Andalusia
      • Córdoba, Andalusia, Espanha, 14004
        • Hospital Universitario Reina Sofia
    • Catalunya [cataluña]
      • Barcelona, Catalunya [cataluña], Espanha, 08036
        • Hospital Clínic de Barcelona
    • LAS Palmas
      • Las Palmas de Gran Canaria, LAS Palmas, Espanha, 35010
        • Hospital Universitario de Gran Canaria Doctor Negrín
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espanha, 28034
        • Hospital Universitario Ramón y Cajal
    • California
      • Encinitas, California, Estados Unidos, 92024
        • California Dermatology & Clinical Research Institute
      • Huntington Beach, California, Estados Unidos, 92647
        • Marvel Clinical Research
      • Los Angeles, California, Estados Unidos, 90056
        • Wallace Medical Group, Inc
    • Florida
      • Boynton Beach, Florida, Estados Unidos, 33436
        • Encore Medical Research of Boynton Beach
      • Hollywood, Florida, Estados Unidos, 33021
        • Skin Care Research
      • Tampa, Florida, Estados Unidos, 33613
        • ForCare Clinical Research
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Dawes Fretzin Clinical Research Group, LLC
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70809
        • DelRicht Research
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20850
        • Lawrence J. Green, MD LLC
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87102
        • University of New Mexico Health Sciences Center
    • New York
      • Brooklyn, New York, Estados Unidos, 11203
        • SUNY Downstate Health Sciences University
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27516
        • University of North Carolina Medical Center
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Clinical & Translational Research Center (CTRC)
      • Wilmington, North Carolina, Estados Unidos, 28411
        • Accellacare - Wilmington
      • Wilmington, North Carolina, Estados Unidos, 28411
        • Wilmington Health, PLLC
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center
      • Columbus, Ohio, Estados Unidos, 43215
        • Remington-Davis, Inc
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
    • Texas
      • Dallas, Texas, Estados Unidos, 75231
        • Modern Research Associates, PLLC
      • Houston, Texas, Estados Unidos, 77056
        • Austin Institute for Clinical Research
      • Houston, Texas, Estados Unidos, 77008
        • Alpesh D. Desai, DO PLLC
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 467-8602
        • Nagoya City University Hospital
    • Miyagi
      • Sendai, Miyagi, Japão, 980-8574
        • Tohoku University Hospital
    • Osaka
      • Sakai, Osaka, Japão, 593-8324
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Bunkyo-ku, Tokyo, Japão, 113-8603
        • Nippon Medical School Hospital
      • Shinjuku-ku, Tokyo, Japão, 160-0023
        • Tokyo Medical University Hospital
    • Yamanashi
      • Kofu, Yamanashi, Japão, 400-8506
        • Yamanashi Prefectural Central Hospital
      • Veracruz, México, 91900
        • Arké SMO S.A de C.V
      • Veracruz, México, 91900
        • Sociedad de Metabolismo y Corazon S.C.
    • Mexico City
      • Mexico City, Mexico City, México, 06720
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey, Nuevo León, México, 64460
        • Centro de Dermatologia de Monterrey
    • Kuyavian-Pomeranian Voivodeship
      • Osielsko, Kuyavian-Pomeranian Voivodeship, Polônia, 86-031
        • DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polônia, 02-962
        • Royalderm Agnieszka Nawrocka
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polônia, 71-500
        • Twoja Przychodnia SCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polônia, 90-436
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polônia, 27-400
        • Dermedic Jacek Zdybski
      • London, Reino Unido, SE1 9RT
        • Guy's & St Thomas' NHS Foundation Trust
      • Istanbul, Turquia (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa
      • Kayseri, Turquia (Türkiye)
        • Erciyes Universitesi Tıp Fakultesi Hastaneleri
      • Manisa, Turquia (Türkiye), 45030
        • Celal Bayar University Hafsa Sultan Hospital
    • İ̇stanbul
      • Istanbul, İ̇stanbul, Turquia (Türkiye), 34899
        • Marmara Universitesi Pendik Egitim Arastirma Hastanesi

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to <18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
  • Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
  • The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040

Exclusion Criteria:

  • Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
  • Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm 1

Participants who previously received 1 ritlecitinib 50 mg capsule QD orally from BL to Week 52 in Study B7981040.

Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned.

Ritlecitinib 50 mg capsule once daily

Ritlecitinib 100 mg capsule once daily

Matching capsule once daily

Experimental: Arm 2

Participants who previously received 1 placebo 50 mg capsule QD orally from BL to Week 52 in Study B7981040 Ritlecitinib 50 mg or Ritlecitinib 100 mg or Placebo will be assigned

Ritlecitinib 50 mg capsule once daily

Ritlecitinib 100 mg capsule once daily

Matching capsule once daily

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation
Prazo: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
Incidence of clinically significant laboratory abnormalities
Prazo: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

To evaluate the long-term safety and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo

Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Response based on T-VASI75 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 75% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI75 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI50 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to Week 52

Proportion of participants achieving at least a 50% improvement in T-VASI from Baseline

Baseline to Week 52
Response based on F-VASI50 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 50% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI90 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 90% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI90 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 90% improvement in F-VASI from Baseline

Baseline to week 52
Response based on T-VASI100 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 100% improvement in T-VASI from Baseline

Baseline to week 52
Response based on F-VASI100 at weeks 4, 8, 12, 24, 36 and 52
Prazo: Baseline to week 52

Proportion of participants achieving at least a 100% improvement in F-VASI from Baseline

Baseline to week 52
Patient Global Impression of Severity-Face (PGIS-F) at weeks 24, 36, and 52
Prazo: Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-F at weeks 24, 36, and 52

Baseline to week 52
Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) at weeks 24, 36, and 52
Prazo: Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Week 24, 36, and 52

Baseline to week 52
Patient Global Impression of Change-Face (PGIC-F) at week 24, 36, and 52
Prazo: Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Week 24, 36, and 52

Baseline to week 52
Patient Global Impression of Change- Overall vitiligo (PGIC-V) at weeks 24, 36, and 52
Prazo: Baseline to week 52

To assess the effect of ritlecitinib compared to placebo on the PGIC-V at weeks 24, 36, and 52

Baseline to week 52
Proportion of participants achieving disease stabilization
Prazo: Baseline to week 52

The difference in the proportion of participants with stable disease at all scheduled timepoints

Baseline to week 52
Percentage change from baseline (%CFB) in F-VASI at weeks 4, 8, 12, 24, 36, and 52
Prazo: Baseline to week 52

To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

Baseline to week 52
Percentage change from baseline (%CFB) in T-VASI at weeks 4, 8, 12, 24, 36, and 52
Prazo: Baseline to week 52

To compare the efficacy of ritlecitinib 100mg QD, 50mg QD, and placebo

Baseline to week 52
Time to loss of response (<F-VASI75 and <T-VASI50 at the same visit).
Prazo: Baseline to week 52

To compare the efficacy of ritlecitinib 100 mg QD, 50 mg QD, and placebo

Baseline to week 52

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Pfizer CT.gov Call Center, Pfizer

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de janeiro de 2024

Conclusão Primária (Estimado)

31 de março de 2027

Conclusão do estudo (Estimado)

31 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de novembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de novembro de 2023

Primeira postagem (Real)

8 de dezembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • B7981041
  • 2023-505804-42-00 (Identificador de registro: CTIS (EU))
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever